GGrantIndex
Sort

39,280 grants matching leukemia

Organizing and Reorganizing Human Testis Development In Vitro

$523,911
Kyle E Orwig · Magee-Women'S Res Inst And Foundation · R01 · FY2024 · HD

PolQ as a novel therapeutic target in AML

$523,880
Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2023 · CA

Ethnic Differences in Survival after Childhood ALL

$523,875
City Of Hope/Beckman Research Institute · R01 · FY2005 · CA

Transcriptional response to signaling during hematopoiesis

$523,832
Leonard I Zon · Boston Children'S Hospital · R01 · FY2022 · HL

Role of Runx1 in Pathologic Ocular Angiogenesis

$523,600
Leo A Kim · Schepens Eye Research Institute · R01 · FY2019 · EY

Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy

$523,587
Weiqiang Chen · New York University · R01 · FY2021 · CA

RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation

$523,510
Catherine Choy Smith · University Of California, San Francisco · R01 · FY2024 · CA

Novel combination therapy for AML expressing mutant RUNX1

$523,503
Courtney Dinardo · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Novel combination therapy for AML expressing mutant RUNX1

$523,503
Courtney Dinardo · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

Wnt signaling in hematopoietic development

$523,447
David Traver · University Of California, San Diego · R01 · FY2018 · HL

Wnt signaling in hematopoietic development

$523,447
David Traver · University Of California, San Diego · R01 · FY2019 · HL

Wnt signaling in hematopoietic development

$523,447
David Traver · University Of California, San Diego · R01 · FY2017 · HL

Wnt signaling in hematopoietic development

$523,447
David Traver · University Of California, San Diego · R01 · FY2020 · HL

Th17 generation, action and therapeutic relevance in chronic lymphocytic leukemia

$523,359
Nicholas Chiorazzi · Feinstein Institute For Medical Research · R01 · FY2020 · CA

Th17 generation, action and therapeutic relevance in chronic lymphocytic leukemia

$523,308
Nicholas Chiorazzi · Feinstein Institute For Medical Research · R01 · FY2024 · CA

The Brooklyn Minority-Based Community Clinical Oncology Program

$523,248
William Barney Solomon · Suny Downstate Medical Center · U10 · FY2009 · CA

Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies

$523,187
John C Byrd · Ohio State University · R01 · FY2017 · CA

Dopaminergic Neuromodulation of Decision Making in Young and Middle-Aged Adults

$523,154
David H Zald · Vanderbilt University · R01 · FY2017 · AG

Studies of Occupational Cancer

$523,142
Qing Lan · Division Of Cancer Epidemiology And Genetics · ZIA · FY2025 · CA

AML mutation-guided drugging of DNA repair

$523,054
Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2024 · CA

Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia Initiation

$523,054
Jennifer Jean Trowbridge · Jackson Laboratory · U01 · FY2024 · AG

In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy

$522,993
Craig Lewis Duvall · Vanderbilt University · R01 · FY2024 · CA

Cytokine control of hematopoiesis and leukemias

$522,984
Lothar Hennighausen · Diabetes, Digestive, Kidney Diseases · Z01 · FY2007 · DK

Inflammation as determinant of clonal selection in MPN progression

$522,957
Nadia Carlesso · Beckman Research Institute/City Of Hope · R01 · FY2021 · HL

BCR-ABL Kinase Assays for STI571 Sensitivity of Response

$522,923
University Of Chicago · R33 · FY2005 · CA